Rakiec, Daniel

Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine

Cancer Genomics and DiagnosticsSingle-cell and spatial transcriptomics

Cited by 507

Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma

Rahal, R., Frick, M., Romero, R., Korn, J. M., Kridel, R., Chun Chan, F., Meissner, B., Bhang, H.-E., Ruddy, D., Kauffmann, A., et al. (2014) · Nature Medicine

Lymphoma Diagnosis and TreatmentNF-κB Signaling Pathways

Cited by 334

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Raoof, S., Mulford, I. J., Frisco-Cabanos, H., Nangia, V., Timonina, D., Labrot, E., Hafeez, N., Bilton, S. J., Drier, Y., Ji, F., et al. (2019) · Oncogene

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 216

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models

Wang, H. Q., Halilovic, E., Li, X., Liang, J., Cao, Y., Rakiec, D. P., Ruddy, D. A., Jeay, S., Wuerthner, J. U., Timple, N., et al. (2017) · eLife

Neuroblastoma Research and TreatmentsLung Cancer Treatments and Mutations

Cited by 45

RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation

Crowe, M. S., Zavorotinskaya, T., Voliva, C. F., Shirley, M. D., Wang, Y., Ruddy, D. A., Rakiec, D. P., Engelman, J. A., Stuart, D. D., & Freeman, A. K. (2021) · Molecular Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 6